Bis[(1S,1′S)-1,1′-(4-amino-4H-1,2,4-triazole-3,5-di­yl)diethanol-κN 1]bis­(nitrato-κO)zinc

In the title homochiral mononuclear compound, [Zn(NO3)2(C6H12N4O2)2], the ZnII atom is located on a twofold rotation axis and coordinated by two N atoms from two ligands and two O atoms from two NO3 − anions, adopting a distorted tetra­hedral coordination geometry. The compound is enanti­omerically pure and corresponds to the S diastereoisomer, with the optical activity originating from the chiral ligand. In the crystal, mol­ecules are connected into three-dimensional supra­molecular networks through O—H⋯O, O—H⋯N and N—H⋯O hydrogen bonds

Extracellular vesicles derived from mesenchymal stem cells: A platform that can be engineered

y. Mesenchymal stem cells play an important role in tissue damage and repair. This role is mainly due to a paracrine mechanism, and extracellular vesicles (EVs) are an important part of the paracrine function. EVs play a vital role in many aspects of cell homeostasis, physiology, and pathology, and EVs can be used as clinical biomarkers, vaccines, or drug delivery vehicles. A large number of studies have shown that EVs derived from mesenchymal stem cells (MSC-EVs) play an important role in the treatment of various diseases. However, the problems of low production, low retention rate, and poor targeting of MSC-EVs are obstacles to current clinical applications. The engineering transformation of MSC-EVs can make up for those shortcomings, thereby improving treatment efficiency. This review summarizes the latest research progress of MSC-EV direct and indirect engineering transformation from the aspects of improving MSC-EV retention rate, yield, targeting, and MSC-EV visualization research, and proposes some feasible MSC-EV engineering methods of transformation

B‐cell maturation antigen chimeric antigen receptor‐T therapy alleviated heart failure in patients with multiple myeloma

Abstract Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N‐terminal pro‐brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%. Anti‐BCMA CAR‐T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N‐terminal pro‐brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse. Herein, we show the efficacy of anti‐BCMA CAR‐T cells in patients with MM and severe heart failure